---
title: "Amgen rises 3% on positive Phase 3 trial data for autoimmune drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299775317.md"
description: "Amgen (AMGN) rose 3% to $403.34 during regular trading on positive Phase 3 autoimmune drug trial results."
datetime: "2026-09-22T13:34:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299775317.md)
  - [en](https://longbridge.com/en/news/299775317.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299775317.md)
generator: "portal-rs"
---

# Amgen rises 3% on positive Phase 3 trial data for autoimmune drug

安进 (AMGN.US) 盘中涨近 3%，现报 403.34 美元。

公司自身免疫药物在后期临床试验中取得成功，推动盘前股价一度涨超 4%。盘中时段该股出现 5 分钟内急涨超 3% 的异动信号，随后涨幅有所收窄。此次三期临床积极数据进一步巩固了安进在生物制药领域的竞争优势。

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease](https://longbridge.com/en/news/299775087.md)
- [Amgen's autoimmune drug succeeds in late-stage trial](https://longbridge.com/en/news/299770733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**